PMID- 22258038
OWN - NLM
STAT- MEDLINE
DCOM- 20120925
LR  - 20181201
IS  - 1699-7980 (Electronic)
IS  - 0210-4806 (Linking)
VI  - 36
IP  - 4
DP  - 2012 Apr
TI  - [Does antibiotherapy prevent unnecessary prostate biopsies in patients with high 
      PSA values?].
PG  - 234-8
LID - 10.1016/j.acuro.2011.07.020 [doi]
AB  - INTRODUCTION: We investigated if antibiotherapy has any role on total PSA (tPSA), 
      free PSA (fPSA) and fPSA/tPSA ratio in patients with tPSA higher than 2.5ng/ml. 
      We also analyzed if it has any relation with prostate cancer diagnosis rate. 
      MATERIAL AND METHODS: A total 108 patients older than 50 years of age with lower 
      urinary system sypmtoms and tPSA >2.5ng/ml were included in this study. 
      Antibiotherapy was given to all the cases for three weeks. After that, 
      transrectal ultrasound-guided prostate biopsies were taken from all the patients. 
      Before and after antibiotherapy, "The International Prostate Symptom Score" 
      (IPSS) and "National Institutes of Health Chronic Prostatitis Symptom Index" 
      (NIH-CPSI) questinories are performed and serum tPSA, fPSA and fPSA/tPSA values 
      were obtained. RESULTS: TPSA, fPSA and fPSA/tPSA ratio alterations prior to and 
      after antibiotherapy did not show any statistically significant difference 
      (p>0.05). When prostate adenocarcinoma was excluded, an statistically significant 
      decrease was found in IPSS and NIH-CPSI scores for all cases. CONCLUSIONS: 
      Antibiotherapy given to patients with PSA levels higher than threshold value has 
      not led to significant change in prostate needle biopsy decision. Prostate biopsy 
      should be considered without trying antibiotherapy in patients with high PSA 
      values if a suspicion of prostatitis does not exist.
CI  - Copyright A(c) 2011 AEU. Published by Elsevier Espana. All rights reserved.
FAU - Faydaci, G
AU  - Faydaci G
AD  - Lutfi Kirdar Training and Research Hospital Urology Clinic, Estambul, Turquia.
FAU - Eryildirim, B
AU  - Eryildirim B
FAU - Tarhan, F
AU  - Tarhan F
FAU - Goktas, C
AU  - Goktas C
FAU - Tosun, C
AU  - Tosun C
FAU - Kuyumcuoglu, U
AU  - Kuyumcuoglu U
LA  - spa
PT  - Clinical Trial
PT  - Journal Article
TT  -  inverted question markEvita la antibioterapia biopsias de prostata en pacientes con valores elevados 
      de PSA?
DEP - 20120117
PL  - Spain
TA  - Actas Urol Esp
JT  - Actas urologicas espanolas
JID - 7704993
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 13T4O6VMAM (Piroxicam)
RN  - A4P49JAZ9H (Ofloxacin)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
CIN - Actas Urol Esp. 2012 Sep;36(8):504. PMID: 22819489
MH  - Adenocarcinoma/blood/diagnosis/pathology
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - *Biopsy, Needle/statistics & numerical data
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Ofloxacin/*therapeutic use
MH  - Piroxicam/therapeutic use
MH  - Predictive Value of Tests
MH  - Prostate/diagnostic imaging/*pathology
MH  - Prostate-Specific Antigen/*blood
MH  - Prostatic Neoplasms/blood/diagnosis/pathology
MH  - Prostatitis/blood/*drug therapy
MH  - Severity of Illness Index
MH  - Ultrasonography, Interventional
MH  - *Unnecessary Procedures
MH  - Urination Disorders/etiology
EDAT- 2012/01/20 06:00
MHDA- 2012/09/26 06:00
CRDT- 2012/01/20 06:00
PHST- 2011/06/02 00:00 [received]
PHST- 2011/07/26 00:00 [revised]
PHST- 2011/07/29 00:00 [accepted]
PHST- 2012/01/20 06:00 [entrez]
PHST- 2012/01/20 06:00 [pubmed]
PHST- 2012/09/26 06:00 [medline]
AID - S0210-4806(11)00355-X [pii]
AID - 10.1016/j.acuro.2011.07.020 [doi]
PST - ppublish
SO  - Actas Urol Esp. 2012 Apr;36(4):234-8. doi: 10.1016/j.acuro.2011.07.020. Epub 2012 
      Jan 17.